drugset / Trial / NCT02264743
Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy
Phase 4
Unknown
60 enrolled
Royal Brompton & Harefield NHS Foundation Trust
Chelsea and Westminster NHS Foundation Trust · collabImperial College Healthcare NHS Trust · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be avoided.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dydrogesterone | Other / unclassified | 2.5 mg | Oral |
| Subject | Estradiol | Other / unclassified | 25 ug | Oral |
| Subject | Estradiol | Other / unclassified | 0.5 mg | Oral |
| Subject | Norethindrone | Unknown | 85 ug | Other |